GlassScriptPhysician profile
Jeffrey Mormol
NPI 1639103377
$1,296.37
in general payments reported to CMS, 2019-2025
25 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $242 · 2021: $195 · 2022: $216 · 2023: $197 · 2024: $163 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $467.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $250.80 | 2019-2024 | Prolia, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $110.34 | 2019-2024 | |
| Abbvie INC. | $103.19 | 2020-2025 | |
| Astellas Pharma US INC | $94.36 | 2023-2025 | Veozah |
| Avion Pharmaceuticals | $93.78 | 2019-2020 | |
| Myovant Sciences INC. | $93.20 | 2021-2022 | |
| Agile Therapeutics, INC. | $79.02 | 2021-2024 | Twirla |
| Exeltis, USA INC. | $58.41 | 2020-2023 | Slynd |
| Organon LLC | $54.62 | 2023-2025 | Nexplanon, Jada System |
| Evofem Biosciences, INC. | $54.17 | 2021 | |
| Exact Sciences Corporation | $39.05 | 2023-2025 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $32.52 | 2022-2023 | Omni Hysteroscope, Fluent Fluid Management System, Novasure |
| Therapeuticsmd, INC. | $31.26 | 2020-2021 | |
| Pfizer INC. | $30.42 | 2020-2024 | |
| Sumitomo Pharma America, INC. | $23.17 | 2025 | Myfembree |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $19.72 | 2022 | |
| Duchesnay USA Incorporated | $16.52 | 2019 | |
| Daiichi Sankyo INC. | $15.07 | 2019 | |
| Covidien LP | $14.93 | 2019 | |
| Mayne Pharma Commercial LLC | $14.69 | 2021 | |
| Lupin INC. | $14.58 | 2020 | |
| Almatica Pharma LLC | $14.17 | 2024 | Teriparatide |
| Biohaven Pharmaceutical Holding Company LTD. | $13.29 | 2022 | |
| Merck Sharp & Dohme LLC | $12.73 | 2020 | |
| Lilly USA, LLC | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Mormol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.